BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology 2018;67:422-35. [PMID: 28881497 DOI: 10.1002/hep.29486] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 24.8] [Reference Citation Analysis]
Number Citing Articles
1 Fang QL, Zhou JY, Xiong Y, Xie CR, Wang FQ, Li YT, Yin ZY, Luo GH. Long non-coding RNA RP11-284P20.2 promotes cell proliferation and invasion in hepatocellular carcinoma by recruiting EIF3b to induce c-met protein synthesis. Biosci Rep 2020;40:BSR20200297. [PMID: 32100822 DOI: 10.1042/BSR20200297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-24. [PMID: 31182766 DOI: 10.1038/s41416-019-0488-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
3 Xie CF, Feng KL, Wang JN, Luo R, Fang CK, Zhang Y, Shen CP, Zhong C. Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling. J Ethnopharmacol 2022;294:115360. [PMID: 35568116 DOI: 10.1016/j.jep.2022.115360] [Reference Citation Analysis]
4 Shi DM, Bian XY, Qin CD, Wu WZ. miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco Targets Ther 2018;11:571-85. [PMID: 29416358 DOI: 10.2147/OTT.S152611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
5 Fan R, Bian M, Hu L, Liu W. A new rhodium(I) NHC complex inhibits TrxR: In vitro cytotoxicity and in vivo hepatocellular carcinoma suppression. Eur J Med Chem 2019;183:111721. [PMID: 31577978 DOI: 10.1016/j.ejmech.2019.111721] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
6 Chou LF, Chen CY, Yang WH, Chen CC, Chang JL, Leu YL, Liou MJ, Wang TH. Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression. Biomolecules 2019;10:E20. [PMID: 31877715 DOI: 10.3390/biom10010020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
7 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
8 Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol 2019;10:e00056. [PMID: 31295152 DOI: 10.14309/ctg.0000000000000056] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 29.5] [Reference Citation Analysis]
9 Yao L, Man CF, He R, He L, Huang JB, Xiang SY, Dai Z, Wang XY, Fan Y. The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers. Front Oncol 2021;11:784127. [PMID: 35070987 DOI: 10.3389/fonc.2021.784127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, Chai Y, Li X, Sun H, Yang R, Cao Y, Feng F, Guo Y. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res 2018;135:188-200. [PMID: 30114438 DOI: 10.1016/j.phrs.2018.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
11 Shi H, Zhou ZM, Zhu L, Chen L, Jiang ZL, Wu XT. Underlying Mechanisms and Related Diseases Behind the Complex Regulatory Role of NOD-Like Receptor X1. DNA Cell Biol 2022. [PMID: 35363060 DOI: 10.1089/dna.2022.0051] [Reference Citation Analysis]
12 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Ke R, Cai Q, Chen Y, Lv L, Jiang Y. Diagnosis and treatment of microvascular invasion in hepatocellular carcinoma. Eur Surg 2020;52:55-68. [DOI: 10.1007/s10353-019-0573-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wirtz TH, Loosen SH, Schulze-Hagen M, Gorgulho J, Kandler J, Joerdens M, Demir M, Mohr R, Bruners P, Kuhl C, Trautwein C, Berres ML, Tacke F, Luedde T, Roderburg C. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. Clin Transl Sci 2021. [PMID: 33787014 DOI: 10.1111/cts.13033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zheng W, Yang J, Dong Z, Wang L, Fang M, Wu W, Yao D, Yao M. High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:5979-5989. [PMID: 30538547 DOI: 10.2147/cmar.s181742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
16 Ogunwobi OO, Kumar A. Chemoresistance Mediated by ceRNA Networks Associated With the PVT1 Locus. Front Oncol 2019;9:834. [PMID: 31508377 DOI: 10.3389/fonc.2019.00834] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
17 Liu Y, Liu MJ, Jiao M, Jiang LL, Fu X, Wang WJ. Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion. Dis Markers 2022;2022:1561607. [PMID: 35730016 DOI: 10.1155/2022/1561607] [Reference Citation Analysis]
18 Wang Y, Chang W, Chang W, Chang X, Zhai S, Pan G, Dang S. MicroRNA-376c-3p Facilitates Human Hepatocellular Carcinoma Progression via Repressing AT-Rich Interaction Domain 2. J Cancer 2018;9:4187-96. [PMID: 30519319 DOI: 10.7150/jca.27939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
19 Lei H, Wang G, Zhang J, Han Q. Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity. Oncol Rep 2018;40:3447-57. [PMID: 30272318 DOI: 10.3892/or.2018.6740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cheng W, Zhang B, Zikeliyar M, Wang J, Jian H, Wu K, Zhang Y, Ding J. Elevated Mortalin correlates with poor outcome in hepatocellular carcinoma. Ann Diagn Pathol 2019;42:59-63. [PMID: 31310900 DOI: 10.1016/j.anndiagpath.2019.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
22 Wang Z, Gu C, Wang X, Lang Y, Wu Y, Wu X, Zhu X, Wang K, Yang H. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma. Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1323-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 2018;9:2650-8. [PMID: 30087705 DOI: 10.7150/jca.25188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
24 Wu Y, Fan W, Xue M, Guo J, Wei J, Wang Y, Yao W, Zhao Y, Li J. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization. Clin Transl Oncol 2020;22:70-80. [DOI: 10.1007/s12094-019-02146-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Wu M, Shi K, Huang R, Liu C, Yin L, Yong W, Sun J, Wang G, Zhong Z, Gao M. Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.01.007] [Reference Citation Analysis]
26 Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
27 Yang B, Feng X, Liu H, Tong R, Wu J, Li C, Yu H, Chen Y, Cheng Q, Chen J, Cai X, Wu W, Lu Y, Hu J, Liang K, Lv Z, Zheng S. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma. Oncogene. 2020;39:6529-6543. [PMID: 32917956 DOI: 10.1038/s41388-020-01450-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
28 Meng J, Gu F, Fang H, Qu B. Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection. J Cancer 2019;10:408-15. [PMID: 30719134 DOI: 10.7150/jca.28409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Schütte K, Schinner R, Fabritius MP, Möller M, Kuhl C, Iezzi R, Öcal O, Pech M, Peynircioglu B, Seidensticker M, Sharma R, Palmer D, Bronowicki JP, Reimer P, Malfertheiner P, Ricke J. Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer 2020;9:771-86. [PMID: 33442545 DOI: 10.1159/000510798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hu YT, Li BF, Zhang PJ, Wu D, Li YY, Li ZW, Shen L, Dong B, Gao J, Zhu X. Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines via regulating Shh-Gli1 signaling. World J Gastroenterol 2019; 25(8): 923-940 [PMID: 30833799 DOI: 10.3748/wjg.v25.i8.923] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Sheng J, Zou X, Cheng Z, Xiang Y, Yang W, Lin Y, Cui R. Recent Advances in Herbal Medicines for Digestive System Malignancies. Front Pharmacol 2018;9:1249. [PMID: 30524272 DOI: 10.3389/fphar.2018.01249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang H, Wu D, Gao C, Teng H, Zhao Y, He Z, Chen W, Zong Y, Du R. Seco-Lupane Triterpene Derivatives Induce Ferroptosis through GPX4/ACSL4 Axis and Target Cyclin D1 to Block the Cell Cycle. J Med Chem 2022. [PMID: 35801495 DOI: 10.1021/acs.jmedchem.2c00664] [Reference Citation Analysis]
33 Yu MC, Liu JX, Ma XL, Hu B, Fu PY, Sun HX, Tang WG, Yang ZF, Qiu SJ, Zhou J, Fan J, Xu Y. Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. Future Oncol 2019;15:3917-34. [PMID: 31729887 DOI: 10.2217/fon-2019-0275] [Reference Citation Analysis]
34 Roy S, Trautwein C, Luedde T, Roderburg C. A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases. Front Pharmacol 2018;9:805. [PMID: 30158867 DOI: 10.3389/fphar.2018.00805] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
35 Loosen SH, Schulze-Hagen M, Bruners P, Tacke F, Trautwein C, Kuhl C, Luedde T, Roderburg C. Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. Cancers (Basel) 2019;11:E1503. [PMID: 31597337 DOI: 10.3390/cancers11101503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
36 Han S, Shi Y, Sun L, Liu Z, Song T, Liu Q. MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1. Int J Biol Sci 2019;15:2936-47. [PMID: 31853229 DOI: 10.7150/ijbs.38000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Dong ZR, Zhou W, Sun D, Yan YC, Yang CC, Yang YF, Li HC, Zhi XT, Li T. Role of the E3 Ubiquitin Ligase TRIM4 in Predicting the Prognosis of Hepatocellular Carcinoma. J Cancer 2020;11:4007-14. [PMID: 32368282 DOI: 10.7150/jca.37164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Tang J, Sui CJ, Wang DF, Lu XY, Luo GJ, Zhao Q, Lian QY, Jeong S, Lin XM, Zhu YJ, Zheng B, Wu R, Wang Q, Liu XL, Liu JF, Xia Q, Wu G, Gu J, Wang HY, Chen L. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics 2020;10:5384-97. [PMID: 32373219 DOI: 10.7150/thno.41616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
40 Tao Y, Shan L, Xu X, Jiang H, Chen R, Qian Z, Yang Z, Liang B, Zheng H, Cai F, Yu Y, Ma L. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J Cancer 2018;9:3962-70. [PMID: 30410600 DOI: 10.7150/jca.25909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
41 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol 2018; 10(9): 558-570 [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
42 Yu JI, Park HC, Yoo GS, Paik SW, Choi MS, Kim HS, Sohn I, Nam H. Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1300. [PMID: 32455607 DOI: 10.3390/cancers12051300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Onco Targets Ther 2020;13:12683-93. [PMID: 33328740 DOI: 10.2147/OTT.S286169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Lin W, Wang H, Zhong M, Yu S, Zhao S, Liang S, Du J, Cheng B, Gu W, Ling C. Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:6529376. [PMID: 33505496 DOI: 10.1155/2021/6529376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zhao Z, Song J, Tang B, Fang S, Zhang D, Zheng L, Wu F, Gao Y, Chen C, Hu X, Weng Q, Yang Y, Tu J, Ji J. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res 2020;39:259. [PMID: 33234142 DOI: 10.1186/s13046-020-01769-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Han Z, He Z, Wang C, Wang Q. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report. Medicine (Baltimore) 2018;97:e13388. [PMID: 30544412 DOI: 10.1097/MD.0000000000013388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Hu B, Yang XB, Sang XT. Development of an immune-related prognostic index associated with hepatocellular carcinoma. Aging (Albany NY) 2020;12:5010-30. [PMID: 32191631 DOI: 10.18632/aging.102926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
48 Loosen SH, Schulze-Hagen M, Vucur M, Gorgulho J, Paffenholz P, Benz F, Mohr R, Demir M, Wree A, Kuhl C, Trautwein C, Tacke F, Bruners P, Luedde T, Roderburg C. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. JGH Open 2021;5:356-63. [PMID: 33732882 DOI: 10.1002/jgh3.12501] [Reference Citation Analysis]
49 Huang F, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol 2018;24:4643-51. [PMID: 30416312 DOI: 10.3748/wjg.v24.i41.4643] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 87] [Article Influence: 23.0] [Reference Citation Analysis]
50 Song W, Zheng C, Liu M, Xu Y, Qian Y, Zhang Z, Su H, Li X, Wu H, Gong P, Li Y, Fan H. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Mol Ther 2021;29:2601-16. [PMID: 33839325 DOI: 10.1016/j.ymthe.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Bian S, Ni W, Zhu M, Song Q, Zhang J, Ni R, Zheng W. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:604766. [PMID: 33363211 DOI: 10.3389/fmolb.2020.604766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
52 Xie Q, Chi S, Fang Y, Sun Y, Meng L, Ding J, Chen Y. PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. Signal Transduct Target Ther 2021;6:130. [PMID: 33785733 DOI: 10.1038/s41392-021-00522-6] [Reference Citation Analysis]
53 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
54 Ma XL, Tang WG, Yang MJ, Xie SH, Wu ML, Lin G, Lu RQ. Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Front Oncol 2020;10:511. [PMID: 32426271 DOI: 10.3389/fonc.2020.00511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
55 Zhao Y, Wang J, Xu C, Li Y, Sun B, Yang L. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling. Clinical Science 2019;133:1645-62. [DOI: 10.1042/cs20190225] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
56 Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma. Transl Cancer Res 2021;10:4636-51. [PMID: 35116320 DOI: 10.21037/tcr-21-1145] [Reference Citation Analysis]
57 Cao Y, Ding W, Zhang J, Gao Q, Yang H, Cao W, Wang Z, Fang L, Du R. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion. J Proteome Res 2019;18:2032-44. [DOI: 10.1021/acs.jproteome.8b00921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
58 Loosen SH, Schulze-Hagen M, Leyh C, Benz F, Vucur M, Kuhl C, Trautwein C, Tacke F, Bruners P, Roderburg C, Luedde T. IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. Int J Mol Sci 2018;19:E1766. [PMID: 29899223 DOI: 10.3390/ijms19061766] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
59 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
60 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
61 Pan J, Xu Y, Wu Q, Hu P, Shi J. Mild Magnetic Hyperthermia-Activated Innate Immunity for Liver Cancer Therapy. J Am Chem Soc 2021;143:8116-28. [PMID: 33928777 DOI: 10.1021/jacs.1c02537] [Reference Citation Analysis]
62 Peng Y, Liu C, Li M, Li W, Zhang M, Jiang X, Chang Y, Liu L, Wang F, Zhao Q. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int 2021;21:98. [PMID: 33568167 DOI: 10.1186/s12935-021-01792-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Song Z, Zhang G, Yu Y, Li S. A Prognostic Autophagy-Related Gene Pair Signature and Small-Molecule Drugs for Hepatocellular Carcinoma. Front Genet 2021;12:689801. [PMID: 34497633 DOI: 10.3389/fgene.2021.689801] [Reference Citation Analysis]
64 Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open 2022;12:e059779. [PMID: 35396315 DOI: 10.1136/bmjopen-2021-059779] [Reference Citation Analysis]
65 Zhang XP, Wang K, Guo WX, Chen ZH, Cheng SQ. Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease? Hepatology 2018;68:786. [PMID: 29500904 DOI: 10.1002/hep.29862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
66 Tang Z, Liu WR, Zhou PY, Ding ZB, Jiang XF, Wang H, Tian MX, Tao CY, Fang Y, Qu WF, Dai Z, Qiu SJ, Zhou J, Fan J, Shi YH. Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. J Cancer 2019;10:5575-84. [PMID: 31632502 DOI: 10.7150/jca.32199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
67 Yan Y, Liang Q, Xu Z, Huang J, Chen X, Cai Y, Peng B, Yi Q. Downregulated Ferroptosis-Related Gene STEAP3 as a Novel Diagnostic and Prognostic Target for Hepatocellular Carcinoma and Its Roles in Immune Regulation. Front Cell Dev Biol 2021;9:743046. [PMID: 34790664 DOI: 10.3389/fcell.2021.743046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent? Cardiovasc Intervent Radiol 2020;43:721-31. [PMID: 32140840 DOI: 10.1007/s00270-020-02434-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Zhao E, Chen S, Dang Y. Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:620765. [PMID: 33553243 DOI: 10.3389/fmolb.2020.620765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Ding B, Lou W, Xu L, Fan W. Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep 2018;38:BSR20180915. [PMID: 30224380 DOI: 10.1042/BSR20180915] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
72 Sun F, Liu Y, Gong T, Pan Q, Xiang T, Zhao J, Tang Y, Chen H, Han Y, Song M, Huang Y, Li H, Chen Y, Yang C, Yang J, Wang Q, Li Y, He J, Weng D, Peng R, Xia J. Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. Cell Death Dis 2021;12:1093. [PMID: 34795209 DOI: 10.1038/s41419-021-04375-3] [Reference Citation Analysis]
73 Zheng W, Yao M, Fang M, Pan L, Wang L, Yang J, Dong Z, Yao D. Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma. J Cancer 2019;10:5862-73. [PMID: 31737122 DOI: 10.7150/jca.31599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
74 Ofosu A, Ramai D, Kurtz LE, Genuth L, Reddy M. Metastatic Hepatocellular Carcinoma into the Transverse Colon. J Gastrointest Cancer 2019;50:644-6. [PMID: 29611036 DOI: 10.1007/s12029-018-0097-0] [Reference Citation Analysis]
75 Xu M, Cui C. Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection. Med Sci Monit 2021;27:e933109. [PMID: 34815375 DOI: 10.12659/MSM.933109] [Reference Citation Analysis]
76 Liao X, Zhan W, Tian B, Luo Y, Gu F, Li R. Circular RNA ZNF609 Promoted Hepatocellular Carcinoma Progression by Upregulating PAP2C Expression via Sponging miR-342-3p. Onco Targets Ther 2020;13:7773-83. [PMID: 32801783 DOI: 10.2147/OTT.S253936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
78 Ye QW, Pang SJ, Yang N, Zhang HB, Fu Y, Lin B, Yang GS. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study. J Gastrointest Surg 2019;23:1549-58. [PMID: 31197690 DOI: 10.1007/s11605-019-04229-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
79 Zhang L, Wang Y, Wang L, Yin G, Li W, Xian Y, Yang W, Liu Q. miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP. Biomedicine & Pharmacotherapy 2018;107:424-32. [DOI: 10.1016/j.biopha.2018.07.155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
80 Cuccurullo V, Di Stasio GD, Mazzarella G, Cascini GL. Microvascular Invasion in HCC: The Molecular Imaging Perspective. Contrast Media Mol Imaging 2018;2018:9487938. [PMID: 30402046 DOI: 10.1155/2018/9487938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
81 Fan Z, Zheng W, Li H, Wu W, Liu X, Sun Z, Hu H, Du L, Jia Q, Liu Q. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells. Oncol Rep 2020;43:1641-9. [PMID: 32323822 DOI: 10.3892/or.2020.7541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Gao X, Wang Y, Li Y, Wang Y, Yan M, Sun H, Chen S, Pan X. Huganpian, a traditional chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest. Biomed Pharmacother 2019;120:109469. [PMID: 31698319 DOI: 10.1016/j.biopha.2019.109469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
83 Liu Z, You Y, Chen Q, Li G, Pan W, Yang Q, Dong J, Wu Y, Bei JX, Pan C, Li F, Li B. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis. Mol Ther 2021:S1525-0016(21)00482-2. [PMID: 34601133 DOI: 10.1016/j.ymthe.2021.07.015] [Reference Citation Analysis]
84 Fang JH, Xu L, Shang LR, Pan CZ, Ding J, Tang YQ, Liu H, Liu CX, Zheng JL, Zhang YJ, Zhou ZG, Xu J, Zheng L, Chen MS, Zhuang SM. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Hepatology 2019;70:824-39. [PMID: 30506570 DOI: 10.1002/hep.30366] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
85 Akimoto T, Ohtake M, Miyake S, Suzuki R, Iida Y, Shimohigoshi W, Higashijima T, Nakamura T, Shimizu N, Kawasaki T, Sakata K, Yamamoto T. Preoperative tumor embolization prolongs time to recurrence of meningiomas: a retrospective propensity-matched analysis. J Neurointerv Surg 2022:neurintsurg-2022-019080. [PMID: 35803729 DOI: 10.1136/neurintsurg-2022-019080] [Reference Citation Analysis]
86 Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, Ni Y. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers (Basel) 2019;11:E1782. [PMID: 31766180 DOI: 10.3390/cancers11111782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
87 Wang T, Zhu H, Xiao M, Zhou S. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma. J Clin Lab Anal 2021;35:e23959. [PMID: 34612554 DOI: 10.1002/jcla.23959] [Reference Citation Analysis]
88 Liao Y, Shao Z, Liu Y, Xia X, Deng Y, Yu C, Sun W, Kong W, He X, Liu F, Guo Z, Chen G, Tang D, Gan H, Liu J, Huang H. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2021;40:201. [PMID: 34154657 DOI: 10.1186/s13046-021-02008-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Malale K, Fu J, Qiu L, Zhan K, Gan X, Mei Z. Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway. Cancer Manag Res 2020;12:4321-33. [PMID: 32606928 DOI: 10.2147/CMAR.S243918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Wu Y, Fan W, Xue M, Zhong B, Zhang S, Wang Y, Yao W, Zhao Y, Li J. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Oncologist 2019;24:e1489-95. [PMID: 31249138 DOI: 10.1634/theoncologist.2018-0669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y, Wu H. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer 2019;18:186. [PMID: 31856849 DOI: 10.1186/s12943-019-1106-z] [Cited by in Crossref: 73] [Cited by in F6Publishing: 88] [Article Influence: 24.3] [Reference Citation Analysis]
92 You R, Jiang H, Xu Q, Yin G. Preintervention MCP-1 serum levels as an early predictive marker of tumor response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Transl Cancer Res 2021;10:966-76. [PMID: 35116424 DOI: 10.21037/tcr-20-2791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Lai Q, Mennini G. Radioembolization in the setting of liver transplantation: great expectations or hard times? Hepatobiliary Surg Nutr 2018;7:58-60. [PMID: 29531949 DOI: 10.21037/hbsn.2017.12.10] [Reference Citation Analysis]
94 Zaidi A, Ahmed S, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Gordon V, Hebbard P, Kim C, Le D, Lee-Ying R, Lim H, Liu D, McGhie JP, Mulder K, Park J, Renouf D, Schellenberg D, Wong RPW, Moser M. Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC. Curr Oncol 2021;28:4317-27. [PMID: 34898545 DOI: 10.3390/curroncol28060367] [Reference Citation Analysis]
95 Liu M, Liu X, Liu S, Xiao F, Guo E, Qin X, Wu L, Liang Q, Liang Z, Li K, Zhang D, Yang Y, Luo X, Lei L, Tan JHJ, Yin F, Zeng X. Big Data-Based Identification of Multi-Gene Prognostic Signatures in Liver Cancer. Front Oncol 2020;10:847. [PMID: 32547951 DOI: 10.3389/fonc.2020.00847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Zeng L, Su J, Qiu W, Jin X, Qiu Y, Yu W. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. Cancer Control 2022;29:10732748221092924. [PMID: 35418272 DOI: 10.1177/10732748221092924] [Reference Citation Analysis]
97 Carr BI. Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Res 2019;5:3. [PMID: 30842979 DOI: 10.20517/2394-5079.2018.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
98 Govalan R, Lauzon M, Luu M, Ahn JC, Kosari K, Todo T, Kim IK, Noureddin M, Kuo A, Walid AS, Sundaram V, Lu SC, Roberts LR, Singal AG, Heimbach JK, Agopian VG, Nissen N, Yang JD. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer 2021;10:407-18. [PMID: 34721504 DOI: 10.1159/000515554] [Reference Citation Analysis]
99 Li X, Zhang X, Li Z, Xie C, Qin S, Yan M, Ke Q, Jin X, Lin T, Zhou M, Liang W, Qi Z, Geng Z, Quan X. Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2021;11:688087. [PMID: 34540664 DOI: 10.3389/fonc.2021.688087] [Reference Citation Analysis]
100 Ma XL, Jiang M, Zhao Y, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Cao Y, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2018;25:1686-94. [PMID: 29626309 DOI: 10.1245/s10434-018-6402-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
101 Shi DM, Li LX, Bian XY, Shi XJ, Lu LL, Zhou HX, Pan TJ, Zhou J, Fan J, Wu WZ. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. J Exp Clin Cancer Res 2018;37:294. [PMID: 30486894 DOI: 10.1186/s13046-018-0957-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
102 Luo Y, Zhang J, Fang L, Zhu Y, You Y, Zhang C, Zheng P, Zhang L, Yin L, Xia F, Bie P, Xie C. FBXW10 promotes hepatocarcinogenesis in male patients and mice. Carcinogenesis 2020;41:689-98. [DOI: 10.1093/carcin/bgz138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
103 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
104 Zhang J, Wang X, Cheng L, Yuan J, Zhong Z. SP94 peptide mediating highly specific and efficacious delivery of polymersomal doxorubicin hydrochloride to hepatocellular carcinoma in vivo. Colloids Surf B Biointerfaces 2021;197:111399. [PMID: 33075660 DOI: 10.1016/j.colsurfb.2020.111399] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Liu H, Lan T, Li H, Xu L, Chen X, Liao H, Chen X, Du J, Cai Y, Wang J, Li X, Huang J, Yuan K, Zeng Y. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics 2021;11:1396-411. [PMID: 33391541 DOI: 10.7150/thno.53227] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 34.0] [Reference Citation Analysis]
106 Xiao F, Li H, Feng Z, Huang L, Kong L, Li M, Wang D, Liu F, Zhu Z, Wei Y, Zhang W. Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade. Sci Rep 2021;11:488. [PMID: 33436794 DOI: 10.1038/s41598-020-80066-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Chen S, Zhao E. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101587. [PMID: 33662631 DOI: 10.1016/j.clinre.2020.101587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Chen B, Xu X, Zheng K, Liu L, Yu Y, Xin Y. Konjac glucomannan reverses multi-drug resistance of HepG2/5-FU cells by suppressing AKT signaling and increasing p53 expression. Oncol Lett 2020;20:2105-12. [PMID: 32782527 DOI: 10.3892/ol.2020.11790] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Xu C, Li YM, Sun B, Zhong FJ, Yang LY. GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway. Carcinogenesis 2021;42:1357-69. [PMID: 34657150 DOI: 10.1093/carcin/bgab098] [Reference Citation Analysis]
110 Huang Y, Xiang B, Liu Y, Wang Y, Kan H. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. 2018;437:56-66. [PMID: 30165194 DOI: 10.1016/j.canlet.2018.08.024] [Cited by in Crossref: 67] [Cited by in F6Publishing: 79] [Article Influence: 16.8] [Reference Citation Analysis]
111 Chen H, Yuan J, Hao J, Wen Y, Lv Y, Chen L, Yang X. α-Humulene inhibits hepatocellular carcinoma cell proliferation and induces apoptosis through the inhibition of Akt signaling. Food Chem Toxicol 2019;134:110830. [PMID: 31562948 DOI: 10.1016/j.fct.2019.110830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
112 Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, Shen YH, Cai JB, Yang Z, Zhou J, Fan J, Sun HC, Kuang M, Huang C. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. J Hematol Oncol 2018;11:28. [PMID: 29482578 DOI: 10.1186/s13045-018-0573-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
113 Luo T, Gao Y, Zhangyuan G, Xu X, Xue C, Jin L, Zhang W, Zhu C, Sun B, Qin X. lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway. Cancer Manag Res 2020;12:5395-408. [PMID: 32753957 DOI: 10.2147/CMAR.S249657] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]